Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Clinical Therapeutics

Volumn 35, Issue 12, 2013, Pages 1997-2006

  Huang, Ze Bing ^a,b   Zhao, Shu Shan ^a   Huang, Yan ^a,b   Dai, Xia Hong ^c   Zhou, Rong Rong ^a,b   Yi, Pan Pan ^a,b   Chen, Ruo Chan ^a,b   Li, Wen Ting ^a,b   Zhang, Bao Xin ^d   Li, Ning ^a   Fan, Xue Gong ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Key Laboratory of Viral Hepatitis   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d Chinese People's Armed Police Forces   (China)

Author keywords

Chronic hepatitis B; Entecavir; Lamivudine plus adefovir; Lamivudine resistance

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; DNA; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; FATIGUE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; NAUSEA; RASH; REVIEW; SEROCONVERSION; SIDE EFFECT; SYSTEMATIC REVIEW; UREA NITROGEN BLOOD LEVEL;

CHRONIC HEPATITIS B; ENTECAVIR; LAMIVUDINE PLUS ADEFOVIR; LAMIVUDINE RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; ORGANOPHOSPHONATES; TREATMENT OUTCOME;

EID: 84890310910     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.10.002     Document Type: Review

References (55)

1. Pawlotsky J.M., Dusheiko G., Hatzakis A., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-415.
2. Liu Y., Wang C., Zhong Y., et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat 2011, 18:e29-e39.
3. Kim H.J., Park J.H., Park D.I., et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010, 25:1374-1380.
4. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
5. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
6. Wang L.C., Chen E.Q., Cao J., et al. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int 2011, 5:671-676.
7. Sayan M., Akhan S.C., Senturk O. Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies. Hepat Mon 2011, 11:835-842.
8. Management of chronic hepatitis B. J Hepatol 2009, 50:227-242. EASL Clinical Practice Guidelines.
9. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
10. Marcellin P., Heathcote E.J., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
11. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-1722.
12. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
13. Ayoub W.S., Keeffe E.B. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008, 28:167-177.
14. Liaw Y.F., Leung N., Guan R., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005, 25:472-489.
15. Ryu H.J., Lee J.M., Ahn S.H., et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010, 82:1835-1842.
16. Locarnini S., Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006, 44:422-431.
17. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005, 25(Suppl 1):9-19.
18. Chang T.T., Lai C.L., Chien R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004, 19:1276-1282.
19. Lee J.H., Yoon J.H., Cho E.J., et al. Simple scoring system predicting genotypic resistance during rescue therapy for lamivudine-resistant chronic hepatitis B. J Clin Gastroenterol 2012, 46:243-250.
20. Liaw Y.F., Chien R.N., Yeh C.T., et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999, 30:567-572.
21. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800-807.
22. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-816.
23. Sheen E., Trinh H.N., Nguyen T.T., et al. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. Aliment Pharmacol Ther 2011, 34:767-774.
24. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
25. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
26. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
27. Degertekin B., Lok A.S. Update on viral hepatitis: 2008. Curr Opin Gastroenterol 2009, 25:180-185.
28. Papatheodoridis G.V., Manolakopoulos S. EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol 2009, 51:226-227.
29. Angus P.W., Patterson S.J., Strasser S.I., et al. Randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48:1460-1466.
30. Sims K.A., Woodland A.M. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy 2006, 26:1745-1757.
31. Shaw T., Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004, 2:853-871.
32. Cheng P.N., Chang T.T. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther 2008, 6:569-579.
33. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
34. Chung G.E., Kim W., Lee K.L., et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamivudine-resistant chronic hepatitis B. Dig Dis Sci 2011, 56:2130-2136.
35. Zhang X.H., Fan G.J. Observation on the effect for two groups of chronic hepatitis with lamifudine-resistent. Chin J Mod Drug Appl 2011, 5:50-51.
36. Tai L.H. The comparison on the effect of entecavir vs lamivudine plus adefovir for chronic hepatitis B with drug-resistant. Chin J Hemorh 2011, 21:298-299.
37. Heo N.Y., Lim Y.S., Lee H.C., et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010, 53:449-454.
38. Luo X.X., Chen K.J. The research on the treatment of lamifudine plus adefovir or entecavir for the patients with the sequential treatment-resistant of lamifudine and adefovir. J Qiqihar Medical Coll 2010, 31:3286-3287.
39. Qiu Y-W, Jiang X-H, Huang L-H, et al. A study on the treatment of chronic hepatitis B with YMDD mutation. Chin J Hepatol 2009, 17:171-174.
40. Zhao S.S., Tang L.H., Dai X.H., et al. Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. Virol J 2011, 8:111.
41. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
42. Higgins J.P., Altman DG., Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
43. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010, 25:603-605.
44. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
45. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
46. Wang S.Q. The comparison on the effect of lamifudine plus adefovir vs entecavir for the initial treatment of patients with hepatitis B. Shandong Medical J 2011, 51:100-101.
47. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
48. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
49. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341. quiz 1286.
50. Woo G., Tomlinson G., Nishikawa Y., et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010, 139:1218-1229.
51. Chang T.T., Lai C.L., Kew Yoon S., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
52. Buti M., Brosa M., Casado M.A., et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009, 51:640-646.
53. Sheng Y.J., Liu J.Y., Tong SW, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 2011, 8:393.
54. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362-366.
55. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-2219.